Research
Hormonal
Weekly subcutaneous semaglutide (2.4 mg) produces significantly greater mean weight loss (15.4%) compared to daily subcutaneous liraglutide (3.0 mg, 6.4%) in patients with overweight or obesity.
If you are struggling with obesity, talk to your doctor about Semaglutide. It is a once-weekly injection that has been shown to help people lose significantly more weight than older medications like Liraglutide. Start with a low dose to minimize side effects and work your way up to the full dose over several months.
GoodSupportsHIGH confidence
The primary outcome of a recent study indicated that the mean weight loss with weekly subcutaneous injections of semaglutide 2.4 mg was 15.4% at week 68, compared to a mean weight loss of 6.4% in those receiving daily subcutaneous liraglutide 3.0 mg.
Why this rating
Based on a cited randomized clinical trial (STEP 8) comparing two active drugs.
Source
Obesity and Current Treatment Approaches: A Comprehensive Review
Karthik Mathialagan et al. · Journal of Translational Gastroenterology · 2024
DOI 10.14218/jtg.2023.00040
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than Semaglutide in patients with type 2 diabetes.Good
- Bariatric surgery (Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) provides effective and sustainable weight loss, with Roux-en-Y showing greater long-term excess weight loss but higher morbidity.Good
- Combination pharmacotherapy for obesity is significantly more effective than monotherapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →